next generation long acting injectibles

Powered by SRGel

Intragel is developing the SRGel long-acting injectable platform for small molecules, peptides and biologics, designed to deliver sustained efficacy with minimal frequency.

SRGel: A Groundbreaking Clinically-Validated Solvent-free LAI Platform

SRGel is a solvent-free long-acting injectable (LAI) platform, designed to enable controlled, extended drug release from a single injection. By shaping the release kinetics, SRGel supports a sustained therapeutic effect while minimizing dose frequency.

With high drug-loading capacity, SRGel can accommodate a broad range of FDA-approved small molecules, peptides and biologics, creating the potential to extend dosing intervals and reduce injection frequency across multiple therapeutic areas.

Our Mission

“At IntraGel, our mission is to improve patient outcomes by transforming how medicines are delivered. We focus on enabling long-acting injectable therapies that can replace daily or weekly dosing with a single administration, or convert large, painful injections into small-volume, highly concentrated doses.

Guided by a patient-first approach, we are developing SRGel™, a long-acting injectable platform designed to support safer, more durable treatment options across multiple therapeutic areas and drug modalities.”

Peter Siman, CEO, and Co-founder, Intragel

About Intragel

At Intragel, we are focused on advancing next-generation long-acting injectable technologies that address some of the most persistent challenges in modern therapeutics. Our work centers on enabling safer, longer-acting injectable treatments through innovative formulation and delivery approaches.

Intragel is led by a multidisciplinary team of experienced scientists and business executives with a strong track record in drug development, formulation, and commercialization. The company operates from the NGT3 technology incubator in Nazareth, Israel, and is building a platform designed to support a broad range of therapeutic applications.